[1] Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease［J］．BMJ,2020,369:m1067. [2] Brito-Zeron P, Ramos-Casals M, Bosch X, et al. The clinical spectrum of IgG4-related disease［J］．Autoimmun Rev,2014,13(12):1203-1210. [3] Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011［J］．Mod Rheumatol,2012,22(1):21-30. [4] Deshpande V, Zen Y, Chan J K, et al. Consensus statement on the pathology of IgG4-related disease［J］．Mod Pathol,2012,25(9):1181-1192. [5] Ebbo M, Grados A, Guedj E, et al. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study［J］．Arthritis Care Res (Hoboken),2014,66(1):86-96. [6] Zhang J, Chen H, Ma Y, et al. Characterizing IgG4-related disease with ¹⁸F-FDG PET/CT: a prospective cohort study.［J］．European journal of nuclear medicine and molecular imaging,2014,41(8). [7] 田孝东，杨尹默，赵玉沛．《中国胰腺癌诊治指南（2021）》解读［J］．中国实用外科杂志，2021,41(07):754-757. [8] 张军．37例 IgG4相关性疾病（IgG4-RD）的临床特征分析［D］．吉林大学，2021. [9] Kamisawa T, Zen Y, Nakazawa T, et al. Advances in IgG4-related pancreatobiliary diseases［J］．Lancet Gastroenterol Hepatol,2018,3(8):575-585. [10] Omar D, Chen Y, Cong Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta analysis［J］．Rheumatology (Oxford),2020,59(4):718-726. [11] Hart P A, Kamisawa T, Brugge W R, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis［J］．Gut,2013,62(12):1771-1776.